DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Denmark
  • /
  • Materials
Author Program NEWCreate Narrative
NSIS B logo

Novozymes A/S Stock Price

CPSE:NSIS B Community·DKK 201.7b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 39 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

NSIS B Share Price Performance

DKK 432.90
28.20 (6.97%)
​
DKK 414.00
Fair Value
DKK 432.90
28.20 (6.97%)
4.6% overvalued intrinsic discount
DKK 414.00
Fair Value
Price DKK 432.90
AnalystLowTarget DKK 414.00
AnalystConsensusTarget DKK 491.93
AnalystHighTarget DKK 540.00
Mon, 24 Aug 26
Fair ValueDKK 414.00
Share Pricen/a

NSIS B Community Narratives

AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value DKK 414 4.6% overvalued intrinsic discount

Bioenergy And Biosolutions Demand Will Support Earnings Despite Regulatory And Competitive Headwinds

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value DKK 491.93 12.0% undervalued intrinsic discount

Enzyme Biosolutions And Preventive Health Trends Will Drive Long-Term Expansion

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value DKK 540 19.8% undervalued intrinsic discount

Emerging Markets And Biofuels Will Support A Stronger Long Term Outlook

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
NSIS B logo
Novozymes
12.0% undervalued intrinsic discount
Updated

Enzyme Biosolutions And Preventive Health Trends Will Drive Long-Term Expansion

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 7 Sep
Read Narrative
NSIS B logo
Novozymes
4.6% overvalued intrinsic discount

Bioenergy And Biosolutions Demand Will Support Earnings Despite Regulatory And Competitive Headwinds

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 24 Aug
Read Narrative
NSIS B logo
Novozymes
19.8% undervalued intrinsic discount

Emerging Markets And Biofuels Will Support A Stronger Long Term Outlook

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 10 Aug
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
NSIS B logo

NSIS B: India Capacity Expansion Will Shape Long Term Upside Potential

Fair Value: DKK 491.93 12.0% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
NSIS B logo

NSIS B: Elevated Expectations Will Hinge On Successful MicroBioGen Integration

Fair Value: DKK 414 4.6% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
NSIS B logo

NSIS B: Consumer Health Probiotics Expansion Will Support Higher Multiple Potential

Fair Value: DKK 540 19.8% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Solid track record with excellent balance sheet and pays a dividend.

1 Risk
3 Rewards
View Full Analysis

Novozymes A/S Key Details

€4.3b

Revenue

€1.9b

Cost of Revenue

€2.4b

Gross Profit

€1.8b

Other Expenses

€631.6m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Nov 05, 2026
1.36
56.39%
14.70%
25.8%
View Full Analysis

About NSIS B

Founded
n/a
Employees
11098
CEO
Ester Baiget
WebsiteView website
www.novonesis.com

Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company also offers bioenergy solutions including biodiesel; biogas from agricultural and industrial residues and food waste; biomass; carbon capture; ethanol for liquefaction, saccharification, fermentation, and fiber conversion; and renewable diesel. In addition, it provides dishwashing, home cleaning, laundry, medical, and industrial and institutional cleaning services; gastrointestinal, immune, mental, women’s, children’s cardiometabolic, and oral human health solutions. Further, the company offers corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; silage, diary and beef cattle, poultry, swine, aquaculture solutions; pet care solutions; leather and textiles solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions; and distilling, oils and fats, sustainable plastic solutions. Additionally, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novozymes A/S is headquartered in Lyngby, Denmark.

Recent NSIS B News & Updates

User avatar
Narrative Update • Sep 07

NSIS B: India Capacity Expansion Will Shape Long Term Upside Potential

The analyst fair value estimate for Novozymes is now DKK 491.93, up DKK 20.88 from the prior DKK 471.06. Analysts are factoring in updated assumptions that align with a series of recent price target increases on Novonesis in the DKK 490 to DKK 535 range.

Recent updates

No updates

Novozymes A/S Competitors

View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide